Treatment of mesenteric desmoid tumours with the anti-oestrogen ic agent toremifene

Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis

“…On the other hand, still poor and often controversial results have been reported as for the treatment of subjects with desmoids. 1,23,32,[52][53][54][55] Our results show that these tumors, even if devoid of metastatic capability, can have a strong impact on survival, particularly when located in the abdominal area. Reported mortality rates for desmoids depend on the length of follow-up and on tumor site and vary between 0% and 29%.…”

Antiangiogenic Treatment of Mesenteric Desmoid Tumors With Toremifene and Interferon Alfa-2b: Report of Two Cases

“…10,[34][35][36] Toremifene, a chlorinated triphenylethylene analog of tamoxifen, has been used for the systemic treatment of mesenteric desmoid tumors and has demonstrated efficacy in ER-negative desmoid tumors. 1 Ovariectomized rats have shown in vivo response in the treatment of ER-negative fibrosarcoma, in which tamoxifen exerted an antiangiogenic effect, suggesting a potential ER-independent mechanism of action. 15 In addition, SERMs were shown to be potent inhibitors of tumor-associated angiogenesis in vivo.…”

Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy

“…For lesions requiring systemic therapy, hormonal therapy including tamoxifen, toremifine, raloxifene, and progestinal agents have been effective in a subset of patients [5-7]. Non-steroidal anti-inflammatory drugs may be used alone or in combination with tamoxifen [8].…”